Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.
Latest financial results
Q2 2025
Quarter Ended Sep 30, 2024
Latest annual filing
For Fiscal Year Ending Mar 31, 2024
Report Links
INVESTOR CONTACTS
Company
Immunovant, Inc.
320 W 37th Street
6th Floor
New York, NY 10018
Investor Relations
Immunovant, Inc.
Investor Relations
info@immunovant.com
Transfer Agent
Continental Stock Transfer & Trust Company, LLC
1 State Street
30th Floor
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com